4169 Taizong Signs Exclusive License Agreement with U.S. Subsidiary TCM Life Science Inc. for U101
NQ Score
87/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Taizong's board has approved an exclusive license agreement with its U.S. subsidiary, TCM Life Science Inc., for the global development and commercialization of U101, with a total contract value of USD 750 million.
AI Analysis
Frequently Asked Questions
- Q: Who is the licensee of U101 from Taizong?
- A: TCM Life Science Inc., a 100%-owned U.S. subsidiary.
- Q: What is the total value of the license agreement?
- A: USD 750 million, including development and sales milestones.
- Q: Where will U101 clinical trials be conducted?
- A: Globally, led by the U.S. subsidiary.
- Q: What triggers the agreement’s effectiveness?
- A: Receipt of funding or sublicense revenue by the subsidiary.
- Q: What strategic benefits does this bring to Taizong?
- A: Risk diversification, global market access, and revenue potential.